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Abstract
Purpose—To evaluate the prevalence of ocular hypertension (OHT) and glaucoma in patients 
with chronic ocular graft-versus-host disease (GVHD).
Methods—We performed a retrospective chart review of 218 patients diagnosed with chronic 
ocular GVHD. Ocular hypertension was defined as intraocular pressure (IOP) ≥ 24 mm Hg in 
either eye without any glaucomatous optic disc changes. Glaucoma suspect was defined as optic 
disc changes with a cup-disc ratio ≥ 0.7 in either eye or asymmetry of ≥ 0.3 between the two eyes. 
Glaucoma was defined by glaucomatous optic disc changes plus glaucomatous visual field defects 
in two consecutive reliable visual field tests. Number of cases of ocular hypertension, glaucoma, 
and glaucoma suspects was evaluated.
Results—Thirty-three patients (15%) were diagnosed with OHT, eight patients (3.6%) with 
suspicion of glaucoma, and one patient (0.4%) with glaucoma. OHT occurred within six months of 
developing ocular GVHD in 60% of the cases and within the first year in 76%. High IOP 
normalized in 67% of patients when the dosage of topical or systemic corticosteroids was lowered, 
and 27% of patients required anti-glaucoma therapy.
Conclusion—Ocular hypertension is a common complication in patients with ocular GVHD, 
with a prevalence of 15%. The rise in intraocular pressure is often transient and resolves with 
management of corticosteroids in most cases. However, clinicians should be aware that nearly one-
third of the patients with OHT might require anti-glaucoma treatment. The prevalences of 
glaucoma and suspicion of glaucoma were not higher than in the general population.
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Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) is extensively used as treatment 
for various malignant and non-malignant hematological disorders [1,2]. Graft-versus-host 
disease (GVHD) is caused by an inflammatory response that occurs when donor derived 
immune cells recognize and attack the recipient’s tissues [3]. GVHD is a multi-organ 
disorder affecting various organs including skin, liver, mouth, gastrointestinal tract and eyes, 
and is a major cause of morbidity after bone marrow transplantation [4]. Ocular GVHD most 
commonly presents with symptoms of chronic dry eye or ocular surface disease, and is 
reported in 40–60% of patients undergoing allogeneic HSCT [5–9].
Ocular hypertension (OHT) and glaucoma have been described as complications during the 
clinical course of various ocular surface inflammatory diseases such as ocular cicatricial 
pempigoid, Stevens-Johnson syndrome, atopic keratoconjunctivitis, and vernal 
keratoconjunctivitis [10–13]. The use of steroids, the presence of inflammation, and scarring 
are some of the suggested mechanisms that lead to increased intraocular pressure (IOP) in 
patients with ocular surface disease [10,12,14,15]. Systemic corticosteroids are a standard 
treatment in many patients with systemic GVHD, and patients with ocular GVHD usually 
receive topical corticosteroids. Limited information is available regarding OHT and 
glaucoma in patients with chronic ocular graft-versus-host disease. The purpose of this study 
is to evaluate the prevalence of ocular hypertension, suspicion of glaucoma, and glaucoma in 
a cohort of patients with chronic ocular graft-versus-host disease.
Methods
We reviewed the medical records of 241 patients with a diagnosis of chronic ocular GVHD 
after allogeneic HSCT and who were part of an oncology protocol according to the records 
at the Cornea Service, Massachusetts Eye and Ear Infirmary (MEEI), between May 2007 
and December 2012. We excluded patients with incomplete records, previous history of 
elevated intraocular pressure, or alterations in the optic disc or visual fields tests. The study 
was approved by the Institutional Review Board and followed the tenets of the Declaration 
of Helsinki. The diagnosis of chronic ocular GVHD was based on history of allogeneic 
HSCT, the presence of systemic graft-versus-host disease in organs other than the eyes, new 
onset (post HSCT) of dry eye symptoms, frequent use of eye drops, and at least two of the 
following: presence of corneal fluorescein staining, tear break-up time ≤ 10 seconds, and 
Schirmer I test score ≤ 10 mm in either eye [16]. The principal diagnosis of all patients 
included in the current study was GVHD-related dry eye. The time of diagnosis of ocular 
GVHD was defined by the date of the patient’s first post-HSCT report of ocular symptoms 
in their medical records, provided that ocular GVHD was later confirmed at the MEEI 
Cornea Clinic.
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For the purpose of this study we defined ‘ocular hypertension’ as IOP ≥ 24 mmHg in either 
eye on at least one examination at our clinic, without evidence of glaucomatous optic disc 
changes [17–20]. IOP measurements were performed with a pneumatonometer (Model 30, 
Reichert Technologies; Depew, NY). Inconsistent readings were, by protocol, systematically 
confirmed by Goldmann applanation tonometry. ‘Suspicion of glaucoma’ was defined as 
optic disc changes with cup-disc ratio ≥ 0.7 in either eye or asymmetry of ≥ 0.3 between the 
two eyes [21–24]. ‘Glaucoma’ was defined as the presence of glaucomatous optic disc 
changes along with corresponding glaucomatous visual field defects in at least two 
consecutive reliable visual field tests. Visual fields were considered to be glaucomatous if a 
reliable visual field test showed a cluster of ≥ 3 points on the pattern deviation plot with a 
sensitivity below 5% [11,25,26]. Temporary elevation of IOP after intraocular surgery or 
laser procedures (e.g., YAG capsulotomy) was not considered as OHT. Descriptive statistics 
are presented as the mean ± standard deviation (SD), median, and range for continuous 
variables, and as percentages for categorical variables.
Results
The final analysis included 218 patients, 124 males and 94 females with a mean age of 52 
± 12 years (range 21–75), with a mean follow-up of 565±540 days (demographic findings 
are shown in Table 1). We excluded 23 patients with incomplete records regarding date of 
HSCT or onset of dry eye symptoms, intraocular pressure and optic disc examination 
(n=13), patients with history of glaucoma prior to bone marrow transplant (4), patients with 
visual field defects due to intracranial pathology (2), and other causes of elevated IOP, such 
as autoimmune uveitis and infectious chorioretinitis (4). Thirty-three patients (15%) 
presented with ocular hypertension, eight patients (3.6%) were diagnosed as glaucoma 
suspects, and one patient (0.4%) with glaucoma. Ocular hypertension was diagnosed at a 
median of 127 days (mean 320±408) after the diagnosis of ocular GVHD. The first episode 
of elevated IOP occurred within six months of developing ocular GVHD in 60% of the cases 
and within the first year in 76%.
From the 33 patients who developed OHT, six patients (18%) were treated with anti-
glaucoma medications and 27 patients (82%) were managed conservatively (reduction in 
corticosteroid therapy). Intraocular pressure returned to normal levels after one episode of 
high IOP in 18 patients (67%) managed conservatively after a median of 62 days (mean 
66±31), with no further IOP elevations or optic disc glaucomatous changes reported in these 
patients during a median follow-up of 311 days (mean 495±472). Seven patients (26%) who 
were managed conservatively developed a second episode of OHT at a median of 55 days 
(mean 135±143) after the first episode. In four patients (57%) who presented a second 
episode of OHT, the IOP returned to normal levels without treatment after a median of 50 
days (mean 63±53) from the second episode, and three patients (43%) required anti-
glaucoma medication. Overall, ocular hypertension resolved in 67% (n=22) of patients 
managed conservatively, 27% (n=9) were treated with anti-glaucoma medications, and 6% 
(n=2) did not have a follow up visit due to hospitalization or death due to complications of 
systemic GVHD.
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Among the 33 patients who developed ocular hypertension, 88% had history of treatment 
with systemic (oral) corticosteroids, 58% with topical corticosteroids. Only 3% had no 
history of treatment with corticosteroids. Among glaucoma suspects, 87% received 
treatment with systemic corticosteroids, 13% with topical corticosteroids, and 13% with 
neither topical nor systemic steroid therapy. The one patient who developed glaucoma had 
been treated only with oral corticosteroids (Table 2).
In general, patients treated with anti-glaucoma medications either had high IOP of ≥30 
mmHg, persistent high IOP ≥24 mmHg for three or more visits, or IOP ≥24 mmHg with 
persistent inflammation that limited tapering of topical or systemic corticosteroids due to 
active systemic or ocular GVHD. Intraocular pressure control was achieved with topical 
anti-glaucoma medications in seven patients, and two patients required laser trabeculoplasty. 
The patient who developed glaucoma responded initially to topical anti-glaucoma therapy 
but later developed vitreous hemorrhage due to concurrent diabetic retinopathy, uncontrolled 
OHT and required glaucoma tube-shunt surgery. Details of anti-glaucoma treatments used in 
this cohort are described in Table 3.
Discussion
This study demonstrates a high prevalence of ocular hypertension in patients with ocular 
graft-versus-host disease. More than 75% of the patients with ocular hypertension 
experienced the first episode of high IOP within a year from the ocular GVHD diagnosis. 
While most of the ocular hypertension episodes were transient and responded to reduction of 
topical or systemic corticosteroids, nearly one third of the patients required anti-glaucoma 
treatment.
The prevalence of ocular hypertension in the general population ranges between 2.7–3.8% 
[21,27–29]. OHT increases with age, from 1.7–2.7% in the age group of 40 to 49 years, 2.7–
4.6% in the 50 to 59 years range, to 4.1–7.5% in people older than 80 years [21,28,29]. In 
the studied cohort with chronic ocular GVHD, ocular hypertension was present in 15% of 
the patients (median age of 54 years), which is significantly higher than that reported in the 
general population for the same age range [21,27–29]. Glaucoma was present in 0.4% of the 
patients, similar to reports in the general population (0.4–5%) [21,29–33]. Similarly, the 
prevalence of glaucoma suspects in the present study (4%) was not significantly different 
than that in the general population (5.6%) [21].
Elevated intraocular pressure in the context of ocular surface disease has been suggested to 
be secondary to a combination of factors that include ocular surface inflammation, 
conjunctival scarring, changes in episcleral venous pressure, and use of topical and systemic 
corticosteroids [10–12]. The corneal epithelium is the most critical barrier of the eye against 
intraocular penetration of topical drugs; therefore, a compromised epithelial function due to 
ocular surface disease likely allows increased absorption of topical corticosteroids, making 
these patients particularly prone to develop OHT [34,35]. One study found a prevalence of 
steroid-induced glaucoma in 0.9% after hematopoietic stem cell transplantation [36]. In the 
present study 97% of the patients who developed OHT had previously been treated with 
corticosteroids, and among these, two thirds resolved without additional therapy after 
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reduction of corticosteroid dosing. Since corticosteroid-induced ocular hypertension is 
usually temporary and responds to discontinuation of the drug [14,37], our findings suggest 
that the IOP rise in patients with ocular GVHD is caused, mainly, by the effect of 
corticosteroids used to treat systemic or ocular GVHD. Moreover, if we exclude the 22 
patients who responded to reduction of systemic or topical corticosteroid administration 
from the overall population with ocular hypertension, the percentage of OHT in the studied 
population (5%) would be comparable to that in the general population [21,27–29]. 
Interestingly, 40% of the patients with OHT and the one patient who developed glaucoma 
had been treated only with systemic corticosteroids before the rise in IOP was detected. 
Although, in general, topical corticosteroids are more likely to cause OHT, studies have 
shown that systemic corticosteroids can increase IOP, especially with high doses or chronic 
use [38–41]. Topical corticosteroids regularly used in the treatment of ocular GVHD-related 
dry eye are milder corticosteroids with less potential to cause OHT than more potent topical 
corticosteroids [42]. This can explain why a considerable group of patients in the studied 
cohort who had only received systemic corticosteroids presented with OHT. This is 
particularly important since approximately half of the patients undergoing allogeneic 
hematopoietic stem cell transplantation will develop systemic GVHD, and most of them, 
will eventually require treatment with long-term systemic corticosteroids [6,43,44]. Still, 
most of these patients are likely to visit the ophthalmologist only in the presence of ocular 
symptoms and, since rise in IOP is generally asymptomatic, the condition may remain 
unnoticed in the absence of regular checkups. The possibility of silent ocular hypertension, 
glaucoma, or irreversible vision loss emphasizes the importance of periodic monitoring in 
patients undergoing HSCT, especially those under treatment with systemic corticosteroids.
Treatment of glaucoma in the context of chronic ocular GVHD disease is challenging due to 
the well-known toxicity of topical anti-glaucoma medications to the ocular surface, which 
can aggravate the underlying ocular surface disease [45,46]. In this study, ocular 
hypertension resolved in 67% of the patients after lowering the dose of topical or systemic 
corticosteroids. Interestingly, one report showed that improvement in the ocular surface 
condition enhanced IOP control in patients with glaucoma and concurrent ocular surface 
disease [15]. The decision to treat ocular hypertension with anti-glaucoma medications 
should weigh the risks of sustained OHT against their toxicity on the ocular surface. In this 
regard, preservative-free anti-glaucoma compounds have significant advantages over 
preserved ones, and should be the first option in cases where conservative management is 
considered insufficient [47,48].
The main limitations of this study relate to its retrospective design. Records of personal and 
family history of glaucoma, past use and dosage of corticosteroids, or specific time of ocular 
symptoms onset (after HSCT) were not available in all cases, as well as details regarding the 
particular reasons for the decision to start anti-glaucoma medications or follow a 
conservative management. Our retrospective analysis is limited by unavailability of corneal 
pachymetry values, to rather confirm corneal thickness is within normal range. However, 
none of the patients in the included cohort presented central corneal scars, 
neovascularization, thinning or conjunctivalization that could, potentially, have altered IOP 
measurements. We were not able to compare the specific types of corticosteroids used by 
patients who developed OHT and by those who did not. Additionally, in general, the 
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majority of patients with chronic GVHD receive corticosteroids in different forms, dosages, 
routes of administration, and frequency, and these patterns of treatment change constantly 
depending on their clinical response. Further controlled prospective studies are required to 
further evaluate the specific risk factors associated with ocular hypertension in patients with 
graft-versus-host disease.
In summary, this study shows that ocular hypertension in patients with ocular graft-versus-
host disease is highly prevalent, while glaucomatous optic neuropathy is uncommon. In 75% 
of the patients with ocular hypertension the rise in intraocular pressure occurs within a year 
after the development of ocular GVHD, but this increase is transitory and responds to 
reduction in the dose of corticosteroids in a large proportion of cases. However, nearly one 
third of the patients with ocular hypertension may require anti-glaucoma treatment. The 
establishment of a protocol that assesses intraocular pressure in patients undergoing HSCT, 
and particularly in those who develop systemic GVHD, should be part of any complete bone 
marrow transplantation program.
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Table 1
Demographics in the studied population
Characteristics N=218
Age, years (mean ± SD) 51±12 years
Gender (%)
 Male 124 (57)
 Female 94 (43)
Race (%)
 Caucasian 169 (78)
 African 4 (2)
 Others 6 (3)
 Unknown 39 (17)
Family history of glaucoma (%)
 Negative 124 (57)
 Positive 23 (10)
 Unknown 71 (33)
SD: standard deviation
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Table 2
Corticosteroid administration route in the patients with ocular hypertension, glaucoma and glaucoma suspects
Corticosteroids Ocular hypertension N=33 (%)* Glaucoma suspects N=8 (%)* Glaucoma N=1 (%)
Systemic (oral) corticosteroids 29 (88) 7 (87) 1 (100)
Topical corticosteroids 19 (58) 1 (13) 0
Both systemic + topical corticosteroids 16 (48) 1 (13) 0
No corticosteroids 1 (3) 1 (13) 0
*
Percentages may not add up to 100% because categories are not mutually exclusive.
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Table 3
Anti-glaucoma therapy in the patients who developed ocular hypertension and glaucoma
Disease Treatment No. of Patients (%)
Ocular Hypertension (N=33)
Topical anti-glaucoma eye drops 7 (21%)
Topical anti-glaucoma eye drops + selective laser trabeculoplasty 2 (6%)
Glaucoma (N= 1) Topical anti-glaucoma eye drops + glaucoma valve surgery 1 (100%)
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